abstract |
The present invention relates to RNAi agents, such as double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit APOC3 expression and to treat subjects with APOC3-related disorders such as hypertriglyceridemia the tester's method. |